Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
Docetaxol-d9; N-Debenzoyl-N-(tert-butoxycarbonyl-d9)-10-deacetyltaxol; RP 56976-d9; Taxotere-d9
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90 %
Hazard Compound
No -Refer MSDS for accurate information
Docetaxel-d9 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Docetaxel-d9 usage and description
Docetaxel D9 is a derivative of Docetaxel, a widely used chemotherapy drug that belongs to the class of taxane drugs. It is primarily used for the treatment of various types of cancer, including breast cancer, lung cancer, prostate cancer, and ovarian cancer, among others. Docetaxel D9 is a deuterated analog of Docetaxel, which means it contains a higher concentration of deuterium atoms, which are heavy isotopes of hydrogen. This modification enhances the stability, solubility, and pharmacokinetic properties of the drug, making it more potent and effective.
The mechanism of action of Docetaxel D9 involves binding to the microtubules in cancer cells, which prevents their normal function of cell division and proliferation. This leads to cell death and tumor regression. Docetaxel D9 is administered intravenously, and the dosage and duration of the treatment depend on the type and stage of cancer, as well as the patient's overall health status.
Chemically, Docetaxel D9 has a molecular formula of C43H53NO14D9 and a molecular weight of 845.06 g/mol. It is a white to pale yellow crystalline powder that is insoluble in water but soluble in ethanol and acetone. The drug has a half-life of approximately 11.1 hours, and it is metabolized in the liver and excreted in the bile and feces. The most common side effects of Docetaxel D9 include nausea, vomiting, hair loss, fatigue, and anemia, among others. However, these side effects are generally manageable and temporary, and they can be minimized with proper medical supervision and supportive care.
